<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/426"/><api:result><api:object category="publication" id="426" last-affected-when="2024-04-13T17:47:44.47+01:00" last-modified-when="2024-04-13T17:47:44.47+01:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/426" created-when="2010-05-17T13:46:19.743+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>1999-03-01</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="1484545" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1016/S0959-8049(98)00403-1" last-modified-when="2022-09-10T11:09:04.98+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="365" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/365"/></api:links><api:last-name>Woll</api:last-name><api:initials>PJ</api:initials><api:first-names>PJ</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Judson</api:last-name><api:initials>I</api:initials><api:first-names>I</api:first-names><api:separate-first-names><api:first-name>I</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lee</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rodenhuis</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Nielsen</api:last-name><api:initials>OS</api:initials><api:first-names>OS</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Buesa</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Leyvraz</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Hermans</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>van Glabbeke</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Verweij</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/s0959-8049(98)00403-1</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/s0959-8049(98)00403-1"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/s0959-8049(98)00403-1"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-8049</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973854"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>European Journal of Cancer</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>410</api:begin-page><api:end-page>412</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier BV</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1016/s0959-8049(98)00403-1</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>22</api:day><api:month>4</api:month><api:year>2019</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>35</api:text></api:field></api:native></api:record><api:record format="native" id="94829" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0033105772" last-modified-when="2023-10-11T06:32:02.047+01:00"><api:citation-count>62</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Temozolomide, an oral imidazotetrazine derivative, was given to 31 patients with advanced soft tissue sarcoma. The dose of 750 mg/m2 was divided over 5 consecutive days, and escalated to 1000 mg/m2 over 5 days at cycle 2 if myelosuppression no worse than common toxicity criteria grade 2 was noted in the first 28-day cycle. A total of 99 treatment cycles were given to 31 patients. The drug was well tolerated, with nausea and vomiting as the most common side-effects. Only one partial tumour response was documented, giving a response rate of 3.33%, 95% confidence interval, (CI) 0.1-17.2%. The median time to progression was 8 weeks and the median survival was 27 weeks. These results indicate that temozolomide in this schedule is not active as second-line treatment in advanced soft tissue sarcoma.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="365" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/365"/></api:links><api:last-name>Woll</api:last-name><api:initials>PJ</api:initials><api:first-names>PJ</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Nottingham City Hospital</api:line><api:line type="city">Nottingham</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7005024157</api:identifier></api:identifiers></api:person><api:person><api:last-name>Judson</api:last-name><api:initials>I</api:initials><api:first-names>I</api:first-names><api:separate-first-names><api:first-name>I</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Royal Marsden Hospital</api:line><api:line type="city">Sutton</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">34975076700</api:identifier></api:identifiers></api:person><api:person><api:last-name>Lee</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">The Christie NHS Foundation Trust</api:line><api:line type="city">Manchester</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7601389313</api:identifier></api:identifiers></api:person><api:person><api:last-name>Rodenhuis</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">The Netherlands Cancer Institute</api:line><api:line type="city">Amsterdam</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7004563254</api:identifier></api:identifiers></api:person><api:person><api:last-name>Nielsen</api:last-name><api:initials>OS</api:initials><api:first-names>OS</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DK"><api:line type="organisation">Aarhus Universitetshospital</api:line><api:line type="city">Aarhus</api:line><api:line type="country">Denmark</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7202851862</api:identifier></api:identifiers></api:person><api:person><api:last-name>Buesa</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="ES"><api:line type="organisation">Hospital Universitario Central de Asturias</api:line><api:line type="city">Oviedo</api:line><api:line type="country">Spain</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7005716572</api:identifier></api:identifiers></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6604053967</api:identifier></api:identifiers></api:person><api:person><api:last-name>Leyvraz</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="CH"><api:line type="organisation">Centre Hospitalier Universitaire Vaudois</api:line><api:line type="city">Lausanne</api:line><api:line type="country">Switzerland</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">57207503010</api:identifier></api:identifiers></api:person><api:person><api:last-name>Hermans</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="BE"><api:line type="organisation">European Organisation for Research and Treatment of Cancer</api:line><api:line type="city">Brussels</api:line><api:line type="country">Belgium</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7005525162</api:identifier></api:identifiers></api:person><api:person><api:last-name>Van Glabbeke</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="BE"><api:line type="organisation">European Organisation for Research and Treatment of Cancer</api:line><api:line type="city">Brussels</api:line><api:line type="country">Belgium</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7004849816</api:identifier></api:identifiers></api:person><api:person><api:last-name>Verweij</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Erasmus MC Cancer Institute</api:line><api:line type="city">Rotterdam</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">55800025000</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/S0959-8049(98)00403-1</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/S0959-8049(98)00403-1"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/S0959-8049(98)00403-1"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10448291</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-8049</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973854"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>European Journal of Cancer</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>410</api:begin-page><api:end-page>412</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Temozolomide in adult patients with advanced soft tissue sarcoma: A phase II study of the EORTC soft tissue and bone sarcoma group</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>35</api:text></api:field></api:native></api:record><api:record format="native" id="426" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10448291" last-modified-when="2020-04-29T04:22:40.56+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Temozolomide, an oral imidazotetrazine derivative, was given to 31 patients with advanced soft tissue sarcoma. The dose of 750 mg/m2 was divided over 5 consecutive days, and escalated to 1000 mg/m2 over 5 days at cycle 2 if myelosuppression no worse than common toxicity criteria grade 2 was noted in the first 28-day cycle. A total of 99 treatment cycles were given to 31 patients. The drug was well tolerated, with nausea and vomiting as the most common side-effects. Only one partial tumour response was documented, giving a response rate of 3.33%, 95% confidence interval, (CI) 0.1-17.2%. The median time to progression was 8 weeks and the median survival was 27 weeks. These results indicate that temozolomide in this schedule is not active as second-line treatment in advanced soft tissue sarcoma.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="365" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/365"/></api:links><api:last-name>Woll</api:last-name><api:initials>PJ</api:initials><api:first-names>PJ</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">City Hospital, Nottingham, U.K. penella.woll@nott.ac.uk</api:line></api:address></api:addresses><api:email-address>penella.woll@nott.ac.uk</api:email-address></api:person><api:person><api:last-name>Judson</api:last-name><api:initials>I</api:initials><api:first-names>I</api:first-names><api:separate-first-names><api:first-name>I</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lee</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rodenhuis</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Nielsen</api:last-name><api:initials>OS</api:initials><api:first-names>OS</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Buesa</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Leyvraz</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Hermans</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>van Glabbeke</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Verweij</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10448291</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/s0959-8049(98)00403-1</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/s0959-8049(98)00403-1"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/s0959-8049(98)00403-1"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-8049</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973854"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Eur J Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents, Alkylating</api:keyword><api:keyword scheme="mesh">Dacarbazine</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Sarcoma</api:keyword><api:keyword scheme="mesh">Survival Analysis</api:keyword><api:keyword scheme="mesh">Temozolomide</api:keyword><api:keyword scheme="mesh">Treatment Outcome</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>England</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>410</api:begin-page><api:end-page>412</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>S0959804998004031</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>23</api:day><api:month>8</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Clinical Trial</api:item><api:item>Clinical Trial, Phase II</api:item><api:item>Journal Article</api:item><api:item>Research Support, Non-U.S. Gov't</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>35</api:text></api:field></api:native></api:record><api:record format="native" id="881839" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10448291" last-modified-when="2024-03-12T19:44:26.207+00:00"><api:citation-count>41</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Temozolomide, an oral imidazotetrazine derivative, was given to 31 patients with advanced soft tissue sarcoma. The dose of 750 mg/m2 was divided over 5 consecutive days, and escalated to 1000 mg/m2 over 5 days at cycle 2 if myelosuppression no worse than common toxicity criteria grade 2 was noted in the first 28-day cycle. A total of 99 treatment cycles were given to 31 patients. The drug was well tolerated, with nausea and vomiting as the most common side-effects. Only one partial tumour response was documented, giving a response rate of 3.33%, 95% confidence interval, (CI) 0.1-17.2%. The median time to progression was 8 weeks and the median survival was 27 weeks. These results indicate that temozolomide in this schedule is not active as second-line treatment in advanced soft tissue sarcoma.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">City Hospital, Nottingham, U.K. penella.woll@nott.ac.uk</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="365" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/365"/></api:links><api:last-name>Woll</api:last-name><api:initials>PJ</api:initials><api:first-names>PJ</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="orcid">0000-0002-1118-0831</api:identifier></api:identifiers></api:person><api:person><api:last-name>Judson</api:last-name><api:initials>I</api:initials><api:first-names>I</api:first-names><api:separate-first-names><api:first-name>I</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lee</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="orcid">0000-0002-1741-6235</api:identifier></api:identifiers></api:person><api:person><api:last-name>Rodenhuis</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Nielsen</api:last-name><api:initials>OS</api:initials><api:first-names>OS</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Buesa</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="orcid">0000-0002-8875-2164</api:identifier></api:identifiers></api:person><api:person><api:last-name>Leyvraz</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Hermans</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>van Glabbeke</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Verweij</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/s0959-8049(98)00403-1</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/s0959-8049(98)00403-1"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/s0959-8049(98)00403-1"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1879-0852</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973854"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10448291</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-8049</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973854"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>European journal of cancer (Oxford, England : 1990)</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Sarcoma</api:keyword><api:keyword scheme="mesh">Dacarbazine</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents, Alkylating</api:keyword><api:keyword scheme="mesh">Treatment Outcome</api:keyword><api:keyword scheme="mesh">Survival Analysis</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Temozolomide</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>410</api:begin-page><api:end-page>412</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>17</api:day><api:month>8</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Clinical Trial, Phase II</api:item><api:item>Clinical Trial</api:item><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>35</api:text></api:field></api:native></api:record><api:record format="native" id="2708581" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1029916651" last-modified-when="2024-04-13T17:47:44.477+01:00"><api:citation-count>64</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="365" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/365"/></api:links><api:last-name>Woll</api:last-name><api:initials>PJ</api:initials><api:first-names>PJ</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">City Hospital</api:line><api:line type="city">Aberdeen</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0672175303.65</api:identifier></api:identifiers><api:author-types><api:author-type>corresponding</api:author-type></api:author-types></api:person><api:person><api:last-name>Judson</api:last-name><api:initials>I</api:initials><api:first-names>I</api:first-names><api:separate-first-names><api:first-name>I</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Royal Marsden Hospital</api:line><api:line type="city">London</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01132707630.61</api:identifier></api:identifiers></api:person><api:person><api:last-name>Lee</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">The Christie Hospital</api:line><api:line type="city">Manchester</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.015307106014.38</api:identifier></api:identifiers></api:person><api:person><api:last-name>Rodenhuis</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Antoni van Leeuwenhoek Hospital</api:line><api:line type="city">Amsterdam</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0707421372.22</api:identifier></api:identifiers></api:person><api:person><api:last-name>Nielsen</api:last-name><api:initials>OS</api:initials><api:first-names>OS</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="DK"><api:line type="organisation">Kommune Hospital, Aarhus, Denmark</api:line><api:line type="city">Arhus</api:line><api:line type="state">Central Jutland</api:line><api:line type="country">Denmark</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0601554735.23</api:identifier></api:identifiers></api:person><api:person><api:last-name>Buesa</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="ES"><api:line type="organisation">Central University Hospital of Asturias</api:line><api:line type="city">Oviedo</api:line><api:line type="country">Spain</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.012556222354.12</api:identifier></api:identifiers></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01223762727.50</api:identifier></api:identifiers></api:person><api:person><api:last-name>Leyvraz</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="CH"><api:line type="organisation">University Hospital of Lausanne</api:line><api:line type="city">Lausanne</api:line><api:line type="country">Switzerland</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01012076341.38</api:identifier></api:identifiers></api:person><api:person><api:last-name>Hermans</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="BE"><api:line type="organisation">European Organisation for Research and Treatment of Cancer</api:line><api:line type="city">Brussels</api:line><api:line type="country">Belgium</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0665737251.21</api:identifier></api:identifiers></api:person><api:person><api:last-name>van Glabbeke</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="BE"><api:line type="organisation">European Organisation for Research and Treatment of Cancer</api:line><api:line type="city">Brussels</api:line><api:line type="country">Belgium</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.077417175.36</api:identifier></api:identifiers></api:person><api:person><api:last-name>Verweij</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Erasmus MC</api:line><api:line type="city">Rotterdam</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01236641403.86</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/s0959-8049(98)00403-1</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/s0959-8049(98)00403-1"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/s0959-8049(98)00403-1"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10448291</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-8049</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973854"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>European Journal of Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3202 Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="rcdc">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="rcdc">Rare Diseases</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="hrcs-rac">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents, Alkylating</api:keyword><api:keyword scheme="mesh">Dacarbazine</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Sarcoma</api:keyword><api:keyword scheme="mesh">Survival Analysis</api:keyword><api:keyword scheme="mesh">Temozolomide</api:keyword><api:keyword scheme="mesh">Treatment Outcome</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>410</api:begin-page><api:end-page>412</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>1.31</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>35</api:text></api:field></api:native></api:record><api:record format="native" id="239947" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000079455000020" last-modified-when="2024-03-14T05:51:36.027+00:00"><api:citation-count>44</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="365" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/365"/></api:links><api:last-name>Woll</api:last-name><api:initials>PJ</api:initials><api:first-names>PJ</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Judson</api:last-name><api:initials>I</api:initials><api:first-names>I</api:first-names><api:separate-first-names><api:first-name>I</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lee</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rodenhuis</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Nielsen</api:last-name><api:initials>OS</api:initials><api:first-names>OS</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Buesa</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Leyvraz</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Hermans</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>van Glabbeke</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Verweij</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000079455000020&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/S0959-8049(98)00403-1</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/S0959-8049(98)00403-1"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/S0959-8049(98)00403-1"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">181RC</api:identifier><api:identifier scheme="pubmed">10448291</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-8049</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973854"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>EUROPEAN JOURNAL OF CANCER</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>chemotherapy</api:keyword><api:keyword>phase II</api:keyword><api:keyword>sarcoma</api:keyword><api:keyword>imidazotetrazine</api:keyword><api:keyword>temozolomide</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>410</api:begin-page><api:end-page>412</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>35</api:text></api:field></api:native></api:record><api:record format="native" id="22476" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000079455000020" last-modified-when="2014-07-25T11:03:11.077+01:00"><api:citation-count>29</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="365" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/365"/></api:links><api:last-name>Woll</api:last-name><api:initials>PJ</api:initials><api:first-names>PJ</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Judson</api:last-name><api:initials>I</api:initials><api:first-names>I</api:first-names><api:separate-first-names><api:first-name>I</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lee</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rodenhuis</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Nielsen</api:last-name><api:initials>OS</api:initials><api:first-names>OS</api:first-names><api:separate-first-names><api:first-name>O</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Buesa</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Leyvraz</api:last-name><api:initials>S</api:initials><api:first-names>S</api:first-names><api:separate-first-names><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Hermans</api:last-name><api:initials>C</api:initials><api:first-names>C</api:first-names><api:separate-first-names><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>van Glabbeke</api:last-name><api:initials>M</api:initials><api:first-names>M</api:first-names><api:separate-first-names><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Verweij</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-8049</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973854"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>EUR J CANCER</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>chemotherapy</api:keyword><api:keyword>phase II</api:keyword><api:keyword>sarcoma</api:keyword><api:keyword>imidazotetrazine</api:keyword><api:keyword>temozolomide</api:keyword><api:keyword>O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE</api:keyword><api:keyword>CHEMOTHERAPY</api:keyword><api:keyword>CELLS</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>410</api:begin-page><api:end-page>412</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>35</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antineoplastic Agents, Alkylating</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Dacarbazine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Sarcoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Survival Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Temozolomide</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Treatment Outcome</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Sarcoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Dacarbazine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antineoplastic Agents, Alkylating</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Treatment Outcome</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Survival Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Temozolomide</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3202 Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Rare Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antineoplastic Agents, Alkylating</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Dacarbazine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Sarcoma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Survival Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Temozolomide</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Treatment Outcome</api:keyword><api:keyword origin="record-data" source="wos-lite">chemotherapy</api:keyword><api:keyword origin="record-data" source="wos-lite">phase II</api:keyword><api:keyword origin="record-data" source="wos-lite">sarcoma</api:keyword><api:keyword origin="record-data" source="wos-lite">imidazotetrazine</api:keyword><api:keyword origin="record-data" source="wos-lite">temozolomide</api:keyword><api:keyword origin="record-data" source="wos">chemotherapy</api:keyword><api:keyword origin="record-data" source="wos">phase II</api:keyword><api:keyword origin="record-data" source="wos">sarcoma</api:keyword><api:keyword origin="record-data" source="wos">imidazotetrazine</api:keyword><api:keyword origin="record-data" source="wos">temozolomide</api:keyword><api:keyword origin="record-data" source="wos">O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE</api:keyword><api:keyword origin="record-data" source="wos">CHEMOTHERAPY</api:keyword><api:keyword origin="record-data" source="wos">CELLS</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="for" origin="issn-inferred">1117 Public Health and Health Services</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword></api:keywords></api:all-labels><api:journal issn="0959-8049" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973854" title="European Journal of Cancer"><api:records><api:record source-name="summary"><api:title>European Journal of Cancer</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/426/relationships"/></api:object></api:result></api:response>